Clinical trials Brief October 15, 2026, 10:03 AM ET

Merck registers Phase 3 trial of ensifentrine for COPD exacerbation prevention

Merck Sharp & Dohme LLC has registered a Phase 3, randomized, double-blind, placebo-controlled study (ENHANCE-3) to evaluate ensifentrine (MK-5884) for preventing moderate and severe COPD exacerbations. The trial plans to enroll 2136 participants, begin on October 23, 2026, and reach primary completion on April 29, 2029.

Primary source

ClinicalTrials.gov registry record, October 15, 2026

Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)

Read the source: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation